-
Mashup Score: 0
The approval was based on the findings from the phase III MSB-GVHD001 clinical study.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet
The approval was based on the findings from the phase III MSB-GVHD001 clinical study.
In @US_FDA approval news reported on #Heme Today: #RemestemcelL for steroid-refractory pediatric acute #GVHD in pts aged two months and older. Approval was based on results from the phase III #MSBGVHD001 study. https://t.co/FrHIwckE0w